Paea LePendu

Paea LePendu

Auto-generated profile, based on publicly available information

Paea LePendu

University of California, Riverside, Riverside, CA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2013 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
RHR Harpaz
R Harpaz
WDW DuMouchel
W DuMouchel
PLP LePendu
P LePendu
ABA Bauer-Mehren
A Bauer-Mehren
PRP Ryan
P Ryan
NSN H Shah
N H Shah

10 June 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NSNigam H Shah
Nigam H Shah
PLPaea LePendu
Paea LePendu
ABAnna Bauer-Mehren
Anna Bauer-Mehren
YGYohannes T Ghebremariam
Yohannes T Ghebremariam
SISrinivasan V Iyer
Srinivasan V Iyer
NLNicholas J Leeper
Nicholas J Leeper
Proton pump inhibitors (PPIs) have been associated with adverse clinical outcomes amongst clopidogrel users after an acute coronary syndrome. Recent pre-clinical results suggest that this risk might extend to subjects without any prior history of cardiovascular disease. We explore this potential risk in the general population via data-mining approaches. Using a novel approach for mining clinical data for pharmacovigilance, we queried over 16 million clinical documents on 2.9 million individuals to examine whether PPI usage was associated with cardiovascular risk in the general population. In multiple data sources, we found gastroesophageal reflux disease (GERD) patients exposed to PPIs to have a 1.16 fold increased association (95% CI 1.09–1.24) with myocardial infarction (MI). Survival analysis in a prospective cohort found a two-fold (HR = 2.00; 95% CI 1.07–3.78; P = 0.031) increase in association with cardiovascular mortality. We found that this association exists regardless of clopidogrel use. We also found that H2 blockers, an alternate treatment for GERD, were not associated with increased cardiovascular risk; had they been in place, such pharmacovigilance algorithms could have flagged this risk as early as the year 2000. Consistent with our pre-clinical findings that PPIs may adversely impact vascular function, our data-mining study supports the association of PPI exposure with risk for MI in the general population. These data provide an example of how a combination of experimental studies and data-mining approaches can be applied to prioritize drug safety signals for further investigation.

20 August 2013 in Circulation
Verified
Journal Article
Closed access
PDF file
YGYohannes T. Ghebremariam
Yohannes T. Ghebremariam
PLPaea LePendu
Paea LePendu
JLJerry C. Lee
Jerry C. Lee
DEDaniel A. Erlanson
Daniel A. Erlanson
ASAnna Slaviero
Anna Slaviero
John Patrick CookeJohn Patrick Cooke
John Patrick Cooke
Background—: Proton pump inhibitors (PPIs) are gastric acid–suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease. Recently, several studies in patients with acute coronary syndrome have raised the concern that use of PPIs in these patients may increase their risk of major adverse cardiovascular events. The mechanism of this possible adverse effect is not known. Whether the general population might also be at risk has not been addressed. Methods and Results—: Plasma asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase. Elevated plasma ADMA is associated with increased risk for cardiovascular disease, likely because of its attenuation of the vasoprotective effects of endothelial nitric oxide synthase. We find that PPIs elevate plasma ADMA levels and reduce nitric oxide levels and endothelium-dependent vasodilation in a murine model and ex vivo human tissues. PPIs increase ADMA because they bind to and inhibit dimethylarginine dimethylaminohydrolase, the enzyme that degrades ADMA. Conclusions—: We present a plausible biological mechanism to explain the association of PPIs with increased major adverse cardiovascular events in patients with unstable coronary syndromes. Of concern, this adverse mechanism is also likely to extend to the general population using PPIs. This finding compels additional clinical investigations and pharmacovigilance directed toward understanding the cardiovascular risk associated with the use of the PPIs in the general population.

24 August 2014 in Drug Safety
Verified
Journal Article
Closed access
PDF file
RHRave Harpaz
Rave Harpaz
ACAlison Callahan
Alison Callahan
STSuzanne Tamang
Suzanne Tamang
YLYen Low
Yen Low
DODavid Odgers
David Odgers
NSNigam H. Shah
Nigam H. Shah

1 March 2014 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
SISrinivasan V Iyer
Srinivasan V Iyer
RHRave Harpaz
Rave Harpaz
PLPaea LePendu
Paea LePendu
ABAnna Bauer-Mehren
Anna Bauer-Mehren
NSNigam H Shah
Nigam H Shah
Background and objective Electronic health records (EHRs) are increasingly being used to complement the FDA Adverse Event Reporting System (FAERS) and

4 March 2013 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
PLP LePendu
P LePendu
SIS V Iyer
S V Iyer
ABA Bauer-Mehren
A Bauer-Mehren
RHR Harpaz
R Harpaz
JMJ M Mortensen
J M Mortensen
NSN H Shah
N H Shah
With increasing adoption of electronic health records (EHRs), there is an opportunity to use the free‐text portion of EHRs for pharmacovigilance. We present novel methods that annotate the unstructur...